Literature DB >> 29992584

Association of IFNλ4 rs12979860 polymorphism with the acquisition of HCV and HIV infections among people who inject drugs.

Ene-Ly Jõgeda1, Radko Avi1, Merit Pauskar1, Eveli Kallas1, Tõnis Karki1, Don Des Jarlais2, Anneli Uusküla3, Karolin Toompere3, Irja Lutsar1, Kristi Huik1.   

Abstract

We investigated the presence of a single-nucleotide polymorphism designated rs12979860 in the interferon λ4 (IFNλ4) gene among 345 people who inject drugs (PWID) and 495 blood donors to evaluate associations between the rs12979860 genotypes and human immunodeficiency virus/hepatitis C virus (HIV/HCV). The rs12979860 TT genotype was over-represented among HIV+ PWID than HIV- PWID and blood donors (16% vs 8% and 10%, P = 0.03, respectively). PWID with TT genotype had approximately twice the probability of being HIV+ (odds ratio [OR], 2.19; 95% confidence interval [CI], 1.11 to 4.33) than PWID without TT. Every additional year of intravenous drug use (IVDU) decreased the OR 1.16 times (OR, 0.86; 95% CI, 0.75 to 0.98). This suggests that rs12979860 TT increases susceptibility to HIV and this impact decreases with increasing duration of IVDU.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Hepatitis C Virus; Human Immunodeficiency Virus; IVDU; Interferons; human immune deficiency virus/hepatitis C virus coinfection; interferon λ; interleukin-28B

Mesh:

Substances:

Year:  2018        PMID: 29992584      PMCID: PMC6158102          DOI: 10.1002/jmv.25258

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  25 in total

1.  Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline.

Authors:  Norma I Rallon; Clara Restrepo; Susanna Naggie; Mariola Lopez; Jorge Del Romero; David Goldstein; John McHutchison; Vincent Soriano; Jose M Benito
Journal:  AIDS       Date:  2011-01-14       Impact factor: 4.177

2.  Effect of Interleukin-28B polymorphism on Interleukin-28 expression and immunological recovery amongst HIV-1-infected individuals following antiretroviral therapy.

Authors:  B V Srinidhi; G John Fletcher; Jaiprasath Sachidanantham; Priscilla Rupali; Veena Vadhini Ramalingam; J P Demosthenes; O C Abraham; Susanne A Pulimood; Grace Rebekah; Rajesh Kannangai
Journal:  Indian J Med Microbiol       Date:  2017 Oct-Dec       Impact factor: 0.985

3.  DAGitty: a graphical tool for analyzing causal diagrams.

Authors:  Johannes Textor; Juliane Hardt; Sven Knüppel
Journal:  Epidemiology       Date:  2011-09       Impact factor: 4.822

4.  Influence of interleukin 10 polymorphisms -592 and -1082 to the HIV, HBV and HCV serostatus among intravenous drug users.

Authors:  Eveli Kallas; Kristi Huik; Merit Pauskar; Ene-Ly Jõgeda; Tõnis Karki; Don Des Jarlais; Anneli Uusküla; Radko Avi; Irja Lutsar
Journal:  Infect Genet Evol       Date:  2014-12-24       Impact factor: 3.342

5.  IFNL4 ss469415590 polymorphism is associated with unfavourable clinical and immunological status in HIV-infected individuals.

Authors:  K Machmach; C Abad-Molina; M C Romero-Sánchez; B Dominguez-Molina; M Moyano; M M Rodriguez; M Rafii-El-Idrissi Benhnia; M E Jimenez-Mejias; F Vidal; M A Muñoz-Fernández; M Genebat; P Viciana; M F González-Escribano; M Leal; E Ruiz-Mateos
Journal:  Clin Microbiol Infect       Date:  2014-10-29       Impact factor: 8.067

6.  Association between TLR3 rs3775291 and resistance to HIV among highly exposed Caucasian intravenous drug users.

Authors:  Kristi Huik; Radko Avi; Merit Pauskar; Eveli Kallas; Ene-Ly Jõgeda; Tõnis Karki; Kristina Marsh; Don Des Jarlais; Anneli Uusküla; Irja Lutsar
Journal:  Infect Genet Evol       Date:  2013-08-17       Impact factor: 3.342

7.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

8.  IL28B gene polymorphisms in mono- and HIV-coinfected chronic hepatitis C patients.

Authors:  Bruna C Bertol; Simone Moreira; Raquel F L Garcia; Leslie E Ferreira; Guilherme Debortoli; Mauro de Souza Leite Pinho; Marcia Amendola-Pires; Alessandra M de Almeida Maciel; Carlos E Brandço-Mello; Paulo H C de França
Journal:  Front Microbiol       Date:  2015-03-04       Impact factor: 5.640

9.  HIV prevalence and risk behaviours among injecting drug users in six indonesian cities implications for future HIV prevention programs.

Authors:  Guy Morineau; Liesbeth Jm Bollen; Rizky Ika Syafitri; Nurjannah Nurjannah; Dyah Erti Mustikawati; Robert Magnani
Journal:  Harm Reduct J       Date:  2012-09-03

10.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Authors:  David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962

View more
  1 in total

1.  IFNL4 genotype influences the rate of HIV-1 seroconversion in men who have sex with men.

Authors:  Giovanna Meza; Fátima Galián; Claudia Jaimes-Bernal; Francisco J Márquez; Faruk Sinangil; Carolina Scagnolari; Luis Miguel Real; Donald Forthal; Antonio Caruz
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.